SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (7792)10/6/2001 2:42:02 PM
From: toccodolce  Read Replies (4) | Respond to of 14101
 
Hi,

So if Dmx owns 20% of OXO Chemie, are they allowed to report 20% of OXO Chemie's earnings or revenue to DMX's bottom line? I ask this because I stumbled upon an article stating that OXO Chemie has won product approval in Thailand for use of WF10. Does anyone know if OXO Chemie has been selling WF10 recently to Thailand. I don't know how old the article is but here is the link:

biospace.com

The direct quote from the article: "In Thailand, the product is already approved for treatment of inflammatory disorders caused by irradiation."

PS. Thailand has about 62 million people.



To: Cal Gary who wrote (7792)10/6/2001 8:36:08 PM
From: Cal Gary  Read Replies (1) | Respond to of 14101
 
According to Note 3, OXO shares are valued for the loan at $11,735 per OXO common share.

$795,000 / 68 = $11,735

A bo-bo, my earlier note should have read:

"By now, this loan could have:
1. been extended (hope not)
2. DMX is in possession of another 204 (3 x 68) Oxo Chemie common (increased ownership)
3. collected $2.3mm + interest
4. any mixture of the above"

Q1 financials may tell if item 3 occurred or not.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News